SCYNEXIS Earnings Call Transcripts
Fiscal Year 2026
-
A special meeting was held to vote on a reverse stock split and reduction of authorized shares, with the proposal approved by shareholders. No additional proposals or questions were raised, and final results will be disclosed in a Form 8-K.
-
Acquisition of SCY-770 marks a strategic shift to rare renal diseases, targeting ADPKD with a promising, selective AMPK activator. The deal provides global rights, strong IP, and financial runway to 2029, positioning the company for leadership in a large, underserved market.
Fiscal Year 2024
-
Key updates included progress on antifungal partnerships, especially with GSK, and advancement of next-generation compound SCY-247 toward first-in-human studies by year-end. The company maintains a strong financial position and is recognized as a leader in antifungal innovation.